South Africa has no blanket ban on research peptide compounds. Most naturally occurring peptides are unscheduled under SAHPRA. But the legal picture has important nuances — and getting them wrong creates real risk. This guide covers everything a South African researcher needs to know.
The South African Health Products Regulatory Authority (SAHPRA) operates under the Medicines and Related Substances Act (Act 101 of 1965, as amended). Their scheduling framework assigns every substance to a schedule — or leaves it unscheduled — determining what level of regulatory control applies.
Schedule 0
Over-the-counter. No supervision required. Vitamins, basic supplements.
Schedule 1–3
Pharmacy-only supply with varying degrees of pharmacist supervision.
Schedule 4
Prescription required from a registered medical practitioner. Cannot be dispensed without a valid script.
Schedule 5–6
Controlled substances (narcotics, psychotropics). Strict prescribing and dispensing controls.
Schedule 7
Prohibited substances. No legitimate supply channel exists.
Unscheduled
Not classified under any schedule. No prescription required. The key category for most research peptides.
The critical point: Being unscheduled does not mean a substance is a free-for-all. A substance can still be regulated by other provisions depending on how it is sold and what claims are made. An unscheduled compound sold with therapeutic claims (treats, cures, prevents disease) becomes an unregistered medicine under the Medicines Act — regardless of scheduling status. The distinction is about how the compound is positioned, not just what it is.
The following compounds are not listed on any SAHPRA schedule as of 2026. No prescription is required for research acquisition. SAHPRA reviews schedules periodically — verify current status before any acquisition.
Status as of May 2026. Always verify before acquisition. This is not legal advice.
“Research use only” is not marketing language or a legal loophole. It is a substantive statement about the purpose and context of the supply transaction — and it has meaningful legal consequences in how the Medicines Act is applied.
It defines the character of the transaction
Supplying an unscheduled compound for research and educational purposes is a different regulatory act from supplying it as a therapeutic product. The former does not invoke the provisions of the Medicines Act that govern medicines registration. The latter does.
It requires genuine declarations
A research-use declaration is not a legal fig leaf. Suppliers and purchasers who sign these declarations are asserting that the purpose is research. Misuse — administering compounds to patients or selling them with therapeutic intent under cover of a research declaration — creates legal exposure for both parties.
It requires age verification
Age verification (18+) at the point of purchase is part of the compliant supply framework. Without it, the supplier is not operating in the same regulatory space as one who implements it. Age-gated, research-declared supply is structurally different from open consumer retail.
It prohibits therapeutic claims
No therapeutic claims anywhere — not on the product page, not in marketing materials, not in follow-up communications. A supplier who says "BPC-157 treats tendon injuries" is making a therapeutic claim that transforms the compound into an unregistered medicine, regardless of its scheduling status.
Unscheduled status is a necessary condition for compliant research supply — it is not a sufficient one. These practices cross legal lines regardless of scheduling status:
THERAPEUTIC CLAIMS
Claiming a compound treats, prevents, or cures any condition makes it a medicine under the Medicines Act. SAHPRA registration is then required. No research peptide carries SAHPRA registration. Therapeutic claims = unregistered medicine = illegal supply.
NO AGE VERIFICATION
Selling research compounds to minors without any age gate is an exposure point. Age verification (18+) is a structural requirement of compliant research supply — not optional.
SELLING SCHEDULED COMPOUNDS WITHOUT PRESCRIPTION INFRASTRUCTURE
Semaglutide, tirzepatide, HGH, IGF-1 are Schedule 4. Supplying these without a valid prescription from a registered practitioner is illegal. Full stop. The fact that they appear in the same online conversations as research peptides does not change their scheduling status.
NO RESEARCH-USE DECLARATION
Without a research-use declaration, the transaction lacks the documented intent that separates research supply from pharmaceutical retail. The supplier has no record that the purchaser understood the research-only nature of the compound.
Schedule 4 — Prescription Required
Semaglutide and tirzepatide are not research peptides. They are registered pharmaceutical drugs with Schedule 4 status under SAHPRA — the same schedule as most prescription medications. They require a valid prescription from a registered South African medical practitioner before they can be legally dispensed or supplied.
Avolvia does not supply semaglutide, tirzepatide, liraglutide, HGH, or IGF-1. These compounds require a pharmaceutical supply chain with prescription infrastructure. Any supplier offering them without that infrastructure is operating illegally under South African law.
Every operational decision at Avolvia is made with the regulatory framework in mind. Four practices are non-negotiable:
01
Age Verification (18+)
Every purchase requires confirmation that the buyer is 18 or older. This is not a checkbox formality — it is a structural requirement that establishes the legal character of every transaction.
02
Research-Use Declaration
Every purchaser confirms that compounds are for research and educational purposes only, not for human consumption. This declaration creates documented intent that separates research supply from pharmaceutical retail.
03
No Therapeutic Claims
No compound on the Avolvia store is described as treating, curing, or preventing any condition. The research literature is described objectively. Mechanisms are explained. Outcomes are not claimed.
04
Third-Party CoA Documentation
Every compound is tested by an independent, accredited laboratory with no commercial interest in the result. CoA documentation is available for all compounds, showing identity by MS, purity by HPLC at 98%+, and lot-specific verification.
Why this matters to you as a researcher: Purchasing from a supplier who has all four of these controls in place means your transaction is documented, your compounds are verified, and the legal character of your purchase is clear. Purchasing from a supplier without these controls means you carry more of the regulatory exposure yourself — and you cannot know what is in the vial.
DISCLAIMER
This guide is for informational purposes only and does not constitute legal advice. Regulatory frameworks change. Always verify the current scheduling status of any compound with SAHPRA or a qualified legal practitioner before acquisition. For specific legal questions, consult a South African attorney with health law experience.
Avolvia supplies pharmaceutical-grade, unscheduled research compounds to verified South African researchers. Third-party tested. Cold-chain delivered. Certificate of Analysis on every compound.
View Compounds18+ only. Research use only. Not for human consumption.